Floatz logo

LIDOCAINE

Cancer-related Pain

National and Kapodistrian University of AthensSmall moleculePhase 2/3Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Cancer-related Pain cohort.

Asset / SponsorPhaseRating
Oxycodone
Deventer Ziekenhuis
Phase 4BB
LIDOCAINE
Instituto Nacional de Cancer, Brazil
Phase 2/3BB
ETHYLICUM
Sindh Institute of Urology and Transplantation
Phase 4BB
NEPENTHE
Instituto Nacional de Cancer, Brazil
Phase 3BB
Tanezumab
Pfizer
Phase 3BB

View all 21 →

Same molecule, other indications

LIDOCAINE is also rated in:

peripheral neuropathyDormant
BBB
Indicative ·
79 / 100
View asset →
postherpetic neuralgiaDormant
BBB
Indicative ·
78 / 100
View asset →
post-operative pain, non-human animalDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →